BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024

Group 1 - BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on genetic diseases [2] - The company will host a call on June 4, 2024, to share results from Month 12 and Month 18 of Cohort 5 of the PROPEL 2 trial [1] - The PROPEL 2 trial is a Phase 2 study investigating the oral therapy infigratinib in children with achondroplasia [1] Group 2 - BridgeBio was founded in 2015 and aims to discover, create, test, and deliver transformative medicines for genetic diseases [2] - The company's pipeline includes programs ranging from early science to advanced clinical trials [2] - BridgeBio's team is committed to applying advances in genetic medicine to help patients quickly [2]